The paper clarifies the reclassification of 'malignant fibrous histiocytoma' as undifferentiated pleomorphic sarcoma, noting that traditional treatments remain applicable.
Answers are grounded in this paper and cite their sources.
Traditional treatments remain appropriate for reclassified undifferentiated pleomorphic sarcoma; confirms classification consensus but leaves open targeted therapy development.
The existence of "malignant fibrous histiocytoma" ("MFH") as a distinct entity is controversial. Previously accepted as the most common sarcoma affecting adults, it is now known to comprise a heterogeneous group of tumors without a specific known line of differentiation. Reclassification of many tumors in this group afforded better prognostication, but traditional treatments still apply. Pleomorphic soft tissue tumors for which a line of differentiation is debatable are presently categorized as undifferentiated pleomorphic sarcoma.
No takes yet. Share an insight, caveat, or question.
Nascimento et al. (2008) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: